Rx DTC ad policy gives consumers "more autonomy," FDA's Friedman maintains.
This article was originally published in The Tan Sheet
Executive Summary
FDA Rx DTC AD POLICY GIVES CONSUMERS "MORE AUTONOMY," FDA's FRIEDMAN suggested during an interview on National Public Radio's "Diane Rehm Show" Jan. 12. "I think that our citizens want more autonomy. They want to be able to make informed choices and decisions," FDA Lead Deputy Commissioner Michael Friedman, MD said. "I think the challenge for FDA is how to get more good information" to consumers. FDA changed its direct-to-consumer advertising policy in August to allow product-and-use ads without a full brief summary requirement ("The Tan Sheet" Aug. 11, 1997, p. 1).